Akeso Biopharma Placement (9926.HK) - Would Investors Be Willing to Take a Gamble?

759 Views20 Mar 2024 20:05
Akeso's valuation has somewhat priced in the success of AK112’s head-to-head trial with KEYTRUDA.But if AK112 fails in critical trials, it will cast a shadow on the entire bispecific antibody pipeline
Boomeranged on Fri, 24 May 2024 10:25
Stock price plunged today because the clinical data of AK112 (EGFRm NSCLC progressed after EGFR-TKI treatment) missed expectations. As we analyzed in the insight, the high valuation of Akeso has already priced in the success of AK112, which, if fails in critical clinical trials, will cast a shadow on the entire bispecific antibody pipeline of Akeso. If you bet, then you need to pay the price.
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
  • Unlock all research summaries
  • Follow top, independent analysts
  • Receive personalised alerts and emails
  • Access Briefings, Analytics, and Events

Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.

Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.

Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
(Paid Plans Only)